Home › Compare › MCJCF vs ABBV
MCJCF yields 40.00% · ABBV yields 3.06%● Live data
📍 MCJCF pulled ahead of the other in Year 1
Combined, MCJCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MCJCF + ABBV for your $10,000?
Majestic Corporation Plc engages in the recycling of catalytic converters, telecom equipment, and printed circuit boards scrap. It recycles precious and non-ferrous metals from obsolete mechanical and industrial materials, including legacy electrical and electronic equipment, precious metals sludge, copper/precious metals residues, electric motors, starters and alternators, shredded motors, wire/cables, aluminum, copper/brass, transformers, and shredded metals. It provides services, such as collection, processing, and the selling of the metals back to the refineries so they can produce the metals back to the supply chain. The company's segment includes solar industries, battery materials, printed circuit boards, platinum group metals refinery, and Non-Ferrous metals recovery. The company also provides recycling services and asset management consultancy to the telecommunications and recycling industries. The company operates in the United States, Malaysia, Italy, Mexico, Australia, the United Kingdom, Hong Kong, and internationally. The company was incorporated in 2021 and is based in Deeside, United Kingdom.
Full MCJCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.